Clinical Trial Update: Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated the efficacy, safety and tolerability of TAK-583 in subjects with postherpetic neuralgia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• TAK-583

Snippet

Sponsor: Takeda | Conditions: Neuralgia, Postherpetic | Phase 2, Phase 3 | Status: COMPLETED